2016 Fiscal Year Final Research Report
Kidney transporter and gut microbiota as therapeutic targets for chronic kidney disease
| Project/Area Number |
26860094
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 尿毒素 / 腸内細菌 / ミトコンドリア / tRNA |
|---|
| Outline of Final Research Achievements |
(1) We comprehensively evaluated serum concentrations of 122 ionic compounds in hemodialysis (HD) patients. We identified 38 solutes and 23 solutes that were higher and lower, respectively, in HD patients than non-dialyzed chronic kidney disease (CKD) patients. (2) We revealed that a newly synthesized indole derivative (MA-5) increased cellular ATP level and survival of fibroblasts from patients with mitochondrial diseases. These data suggest that MA-5 has the potential to become a novel therapeutic drug for treatment of mitochondrial diseases. (3) We revealed that ClC-2 chloride channel activator lubiprostone improved the gut microbiota, resulting in amelioration of CKD progression. (4) Using next-generation sequencing, we examined whether ribonuclease angiogenin (ANG) cleaves CCA-termini of tRNAs in vivo. The proportion of tRNA-derived fragments with CCA did not increase in ANG-treated cells, suggesting that ANG does not cleave CCA-termini in vivo.
|
| Free Research Field |
腎臓病学
|
